Adipokines as Drug Targets in Diabetes and Underlying Disturbances

DSpace/Manakin Repository

Adipokines as Drug Targets in Diabetes and Underlying Disturbances

Citable link to this page

 

 
Title: Adipokines as Drug Targets in Diabetes and Underlying Disturbances
Author: Andrade-Oliveira, Vinícius; Câmara, Niels O. S.; Moraes-Vieira, Pedro M.

Note: Order does not necessarily reflect citation order of authors.

Citation: Andrade-Oliveira, Vinícius, Niels O. S. Câmara, and Pedro M. Moraes-Vieira. 2015. “Adipokines as Drug Targets in Diabetes and Underlying Disturbances.” Journal of Diabetes Research 2015 (1): 681612. doi:10.1155/2015/681612. http://dx.doi.org/10.1155/2015/681612.
Full Text & Related Files:
Abstract: Diabetes and obesity are worldwide health problems. White fat dynamically participates in hormonal and inflammatory regulation. White adipose tissue is recognized as a multifactorial organ that secretes several adipose-derived factors that have been collectively termed “adipokines.” Adipokines are pleiotropic molecules that gather factors such as leptin, adiponectin, visfatin, apelin, vaspin, hepcidin, RBP4, and inflammatory cytokines, including TNF and IL-1β, among others. Multiple roles in metabolic and inflammatory responses have been assigned to these molecules. Several adipokines contribute to the self-styled “low-grade inflammatory state” of obese and insulin-resistant subjects, inducing the accumulation of metabolic anomalies within these individuals, including autoimmune and inflammatory diseases. Thus, adipokines are an interesting drug target to treat autoimmune diseases, obesity, insulin resistance, and adipose tissue inflammation. The aim of this review is to present an overview of the roles of adipokines in different immune and nonimmune cells, which will contribute to diabetes as well as to adipose tissue inflammation and insulin resistance development. We describe how adipokines regulate inflammation in these diseases and their therapeutic implications. We also survey current attempts to exploit adipokines for clinical applications, which hold potential as novel approaches to drug development in several immune-mediated diseases.
Published Version: doi:10.1155/2015/681612
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397001/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:15035042
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters